Medivir AB (MVIR B) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Cantargia AB

Oncopeptides AB

Xbrane Biopharma AB

Medivir AB

Orexo AB

Cereno Scientific AB

Diamyd Medical AB

SynAct Pharma AB

FluoGuide A/S

Initiator Pharma A/S

Kancera AB

Why is Medivir AB ?

Poor long term growth as Net Sales has grown by an annual rate of -21.94% over the last 5 years

The company has declared Negative results for the last 3 consecutive quarters

NET SALES(HY) At SEK 1.6 MM has Grown at -67.35%
OPERATING CASH FLOW(Y) Lowest at SEK -115.89 MM
CASH AND EQV(HY) Lowest at SEK 97.63 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -84.03%, its profits have risen by 7.6%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -84.03% returns in the last 1 year, the stock has also underperformed OMX Stockholm 30 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Medivir AB for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Medivir AB

-85.77%

-0.91

93.91%

OMX Stockholm 30

8.01%

0.51

18.11%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-21.94%

EBIT Growth (5y)

0.35%

EBIT to Interest (avg)

-78.25

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.34

Sales to Capital Employed (avg)

0.04

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.77

EV to EBIT

-0.24

EV to EBITDA

-0.24

EV to Capital Employed

0.56

EV to Sales

5.84

PEG Ratio

Dividend Yield

ROCE (Latest)

-239.86%

ROE (Latest)

-122.99%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -59.84% (YoY

OPERATING PROFIT(Q)

Highest at SEK -12.5 MM

PRE-TAX PROFIT(Q)

Highest at SEK -13.3 MM

NET PROFIT(Q)

Highest at SEK -13.3 MM

EPS(Q)

Highest at SEK -0.12

-13What is not working for the Company

NET SALES(HY)

At SEK 1.6 MM has Grown at -67.35%

OPERATING CASH FLOW(Y)

Lowest at SEK -115.89 MM

CASH AND EQV(HY)

Lowest at SEK 97.63 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 0.83%

Here's what is working for Medivir AB

Operating Profit

Highest at SEK -12.5 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (SEK MM)

Pre-Tax Profit

Highest at SEK -13.3 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (SEK MM)

Pre-Tax Profit

At SEK -13.3 MM has Grown at 49.04%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (SEK MM)

Net Profit

Highest at SEK -13.3 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (SEK MM)

Net Profit

At SEK -13.3 MM has Grown at 49.04%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (SEK MM)

EPS

Highest at SEK -0.12

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (SEK)

Raw Material Cost

Fallen by -59.84% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Medivir AB

Net Sales

At SEK 1.6 MM has Grown at -67.35%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (SEK MM)

Operating Cash Flow

Lowest at SEK -115.89 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (SEK MM)

Cash and Eqv

Lowest at SEK 97.63 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio

Lowest at 0.83%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio